These findings are bolstered by a 2015 report of a DSRCT patient treated with HER2 CAR T cells in a basket trial for sarcoma patients who had stable disease for over 14 months after the initial infusion (Ahmed et al., 2015). The gene discussed is ERBB2; the disease is sarcoma.